BI
TCRX icon

BVF Inc’s TScan Therapeutics TCRX Stock Holding History

BVF Inc’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.62M Buy
5,564,290
+338,216
+6% +$361K 0.18% 36
2025
Q4 		$5.23M Hold
5,226,074
– – 0.18% 37
2025
Q3 		$9.51M Hold
5,226,074
– – 0.39% 34
2025
Q2 		$7.58M Buy
5,226,074
+336,600
+7% +$486K 0.27% 34
2025
Q1 		$6.75M Buy
4,889,474
+1,900,000
+64% +$4.11M 0.28% 38
2024
Q4 		$9.09M Hold
2,989,474
– – 0.31% 38
2024
Q3 		$14.9M Hold
2,989,474
– – 0.44% 32
2024
Q2 		$17.5M Hold
2,989,474
– – 0.49% 35
2024
Q1 		$23.7M Hold
2,989,474
– – 0.65% 32
2023
Q4 		$17.4M Hold
2,989,474
– – 0.44% 40
2023
Q3 		$7.65M Hold
2,989,474
– – 0.21% 49
2023
Q2 		$7.47M Buy
+2,989,474
New +$8.02M 0.21% 48

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

BVF Inc's TCRX Position: Q1 2026 in Review

BVF Inc increased its TScan Therapeutics (TCRX) stake by 6.5% in Q1 2026, buying an estimated $361K and bringing the position to 5,564,290 shares worth $5.62M. The position accounts for 0.18% of the portfolio, ranked #36.

BVF Inc first reported a position in TCRX in Q2 2023 and has held it in 12 quarters since. The position peaked at $23.7M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • BVF Inc held 5,564,290 shares of TScan Therapeutics worth $5.62M as of Q1 2026.
  • BVF Inc bought 338,216 TScan Therapeutics shares in Q1 2026, an estimated $361K.
  • TScan Therapeutics made up 0.18% of BVF Inc's portfolio in Q1 2026, its #36 holding.
  • BVF Inc first reported a position in TScan Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • BVF Inc's TScan Therapeutics position peaked at $23.7M in Q1 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on BVF Inc's 13F filing for Q1 2026, filed 15 May 2026.